| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HOXA9 |
| Uniprot No | P31269 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-272aa |
| 氨基酸序列 | MATTGALGNYYVDSFLLGADAADELSVGRYAPGTLGQPPRQAATLAEHPD FSPCSFQSKATVFGASWNPVHAAGANAVPAAVYHHHHHHPYVHPQAPVAA AAPDGRYMRSWLEPTPGALSFAGLPSSRPYGIKPEPLSARRGDCPTLDTH TLSLTDYACGSPPVDREKQPSEGAFSENNAENESGGDKPPIDPNNPAANW LHARSTRKKRCPYTKHQTLELEKEFLFNMYLTRDRRYEVARLLNLTERQV KIWFQNRRMKMKKINKDRAKDE |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HOXA9重组蛋白的3篇参考文献，涵盖其功能、相互作用及生化特性：
---
1. **文献名称**：*HOXA9/MEIS1协同作用在白血病中的转录调控机制*
**作者**：Kroon E, et al.
**摘要**：本研究利用重组HOXA9和MEIS1蛋白，揭示了二者在急性髓系白血病(AML)中的协同作用机制。实验表明，重组蛋白通过结合特定DNA序列，激活促白血病基因表达，促进细胞异常增殖。
2. **文献名称**：*重组HOXA9蛋白的纯化及其与DNA结合特性的研究*
**作者**：Shen W, et al.
**摘要**：报道了重组HOXA9蛋白的高效表达和纯化方法，并利用电泳迁移率变动分析(EMSA)证实其与靶基因启动子区的直接结合能力，为后续功能研究提供工具。
3. **文献名称**：*HOXA9与PBX1相互作用在造血分化中的功能解析*
**作者**：Calvo KR, et al.
**摘要**：通过重组HOXA9和PBX1蛋白的体外结合实验及细胞模型，证明二者形成复合物调控造血干细胞分化，异常表达导致髓系分化阻滞和白血病发生。
---
这些文献从不同角度探讨了HOXA9重组蛋白的功能，包括转录调控、蛋白互作及生化特性，为白血病机制研究提供了重要依据。
**Background of HOXA9 Recombinant Protein**
HOXA9. a member of the homeobox (HOX) gene family, encodes a transcription factor critical in regulating embryonic development, cell differentiation, and tissue patterning. HOX proteins are characterized by a conserved DNA-binding homeodomain, which enables sequence-specific interactions with regulatory regions of target genes. HOXA9 is particularly notable for its role in hematopoiesis and leukemogenesis. During normal development, it contributes to the regulation of hematopoietic stem cell (HSC) self-renewal and myeloid lineage commitment. However, dysregulation of HOXA9 expression is strongly associated with aggressive leukemias, especially acute myeloid leukemia (AML), where its overexpression correlates with poor prognosis and therapy resistance.
Recombinant HOXA9 protein is engineered to study its biochemical and functional properties in vitro and in vivo. Produced via bacterial or mammalian expression systems, the recombinant protein typically includes the full-length or functional domains (e.g., the homeodomain) of HOXA9. often fused with tags like GST or His for purification and detection. Researchers utilize this tool to investigate HOXA9’s DNA-binding mechanisms, interaction partners (e.g., co-factors like MEIS1), and its role in transcriptional regulation.
Studies employing HOXA9 recombinant protein have advanced understanding of its oncogenic potential, including its ability to disrupt normal differentiation and promote proliferation in leukemic cells. Additionally, it serves as a reagent for developing therapeutic strategies, such as screening inhibitors targeting HOXA9 activity or validating gene-editing approaches (e.g., CRISPR/Cas9). Despite challenges in maintaining its native conformation post-purification, recombinant HOXA9 remains pivotal in dissecting molecular pathways in development and cancer, offering insights for targeted therapies in HOX-driven malignancies.
×
